Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting: I nterim (1-year) report from a Japanese post-marketing surveillance study-Reference-Cited by-同舟云学术

Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting: I nterim (1-year) report from a Japanese post-marketing surveillance study

Published:2017-08-01 Issue:1 Volume:11 Page:14-23
ISSN:1757-5664
Container-title:LUTS: Lower Urinary Tract Symptoms
language:en
Short-container-title:Lower Urinary Tract Symptoms

Author:

Kato Daisuke¹,Tabuchi Hiromi²,Uno Satoshi³

Affiliation:

1. Medical Science, Medical Affairs; Astellas Pharma Inc.; Tokyo Japan

2. Medical Research, Medical Affairs; Astellas Pharma Inc.; Tokyo Japan

3. Japan-Asia Data Science, Development; Astellas Pharma Inc.; Tokyo Japan

Funder

Astellas Pharma Inc

Astellas Pharma Global Development

Publisher

Wiley

Subject

Urology,Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/luts.12188/fullpdf

Reference47 articles.

1. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013;Drake;Neurourol Urodyn,2014

2. Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review;Bartoli;Urology,2010

3. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction;Irwin;BJU Int,2011

4. Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life;Jayarajan;Res Rep Urol,2013

5. Health related quality of life in patients with side-effects after antimuscarinic treatment for overactive bladder;Kim;Low Urin Tract Symptoms,2016

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How can we explain the poor medication adherence in patients with overactive bladder syndrome?;Hellenic Urology;2024-07

2. Efficacy of transcutaneous electrical nerve stimulation combined with mirabegron therapy compared with mirabegron monotherapy for overactive bladder: a prospective randomized controlled study;World Journal of Urology;2024-06-07

3. Treatment Patterns with Mirabegron and Antimuscarinics for Overactive Bladder: A Prospective, Registry Study in Taiwan and South Korea (FAITH);Advances in Therapy;2024-03-02

4. Metabolic and cardiovascular features of the course of type 2 diabetes mellitus in men with hypogonadism;Meditsinskiy sovet = Medical Council;2022-06-18

5. Diagnosis and management of overactive bladder: A review;Journal of Obstetrics and Gynaecology Research;2021-02-16